Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

HLA-A*11:01 (Monomer) protein (Biotin,KRAS)

Origine: Humain Hôte: HEK-293 Cells Recombinant > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
N° du produit ABIN7454303
  • Antigène
    HLA-A*11:01
    Type de proteíne
    Recombinant
    Attributs du protein
    Monomer
    Origine
    Humain
    Source
    • 31
    • 6
    • 1
    HEK-293 Cells
    Purification/Conjugué
    Biotin,KRAS
    Fonction
    Biotinylated Human HLA-A*11:01 & B2M & KRAS WT (VVVGAGGVGK) Monomer Protein
    Séquence
    Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVVGAGGVGK peptide
    Specificité
    Uni-Prot: AAV53343.1 (HLA-A*11:01), P61769 (B2M), VVVGAGGVGK
    Attributs du produit
    Recombinant Biotinylated Human HLA-A*11:01 & B2M & KRAS WT (VVVGAGGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M) and VVVGAGGVGK peptide.
    Pureté
    > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
    Stérilité
    0.22 μm filtered
    niveau d'endotoxine
    Less than 1EU per μg by the LAL method.
  • Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.
    Buffer
    Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.
    Stock
    -20 °C,-80 °C
    Stockage commentaire
    -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Date de péremption
    12 months
  • Antigène
    HLA-A*11:01
    Sujet
    Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
    Poids moléculaire
    50.30 kDa. Due to glycosylation, the protein migrates to 53-63 kDa based on Tris-Bis PAGE result.
Vous êtes ici:
Support technique